Trial Profile
Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary)
- Indications Histiocytosis
- Focus Registrational; Therapeutic Use
- 12 Dec 2023 Results (n=26; data cutoff date: 28 Sep 2019) reporting safety and efficacy data presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 19 Dec 2022 Status changed from recruiting to completed.
- 07 Jul 2021 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.